Résultats de la recherche

search
tiziana-logo.png
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
27 févr. 2025 08h00 HE | Tiziana Life Sciences Ltd.
Traumatic brain injury is a leading cause of death and disabilityCurrently, there is no treatment to prevent the long-term effects of traumatic brain injuryFindings could translate into treating...
tiziana-logo.png
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
25 févr. 2025 08h00 HE | Tiziana Life Sciences Ltd.
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
tiziana-logo.png
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
18 févr. 2025 08h00 HE | Tiziana Life Sciences Ltd.
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
tiziana-logo.png
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
18 avr. 2024 07h00 HE | Tiziana Life Sciences Ltd.
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
tiziana-logo.png
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
11 avr. 2024 07h00 HE | Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the American Academy of Neurology
Figure 1
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
13 oct. 2023 07h00 HE | Tiziana Life Sciences Ltd.
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)Foralumab to advance into Phase 2 human...
tiziana-logo.png
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
06 sept. 2023 07h00 HE | Tiziana Life Sciences Ltd.
The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...
Figure 1
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
05 juin 2023 10h00 HE | Tiziana Life Sciences Ltd.
Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvementsPhase 2a trial in na-SPMS on track to begin in Q3...
tiziana-logo.png
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
13 avr. 2023 07h00 HE | Tiziana Life Sciences Ltd.
Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trillionThe role of activated microglia is well-established...